Ocugen, Inc. (NASDAQ: OCGN) has announced that the first patient has been dosed in its Phase 2/3 GARDian3 clinical trial ...

In early research, OCU410ST, a gene therapy for Stargardt disease, demonstrated slowed lesion growth by 48% at the 12-month follow-up in evaluable treated eyes.

BACKGROUND: Neurodevelopmental and functional impairments are among the most consequential morbidities for survivors of ...

Dementia associated with Alzheimer’s disease is a progressive neurodegenerative condition characterized by memory loss, cognitive decline, and impaired daily functioning. The growing aging population ...

New leadership to spearhead AI-driven breakthroughs in drug discovery and operational excellence Austin, Texas--(Newsfile ...

Moleculin Biotech, Inc. 40+ year career at Roche founded on dedication to bringing new innovative medicines to patients and ...

Shelton, Connecticut Thursday, July 17, 2025, 18:00 Hrs [IST] ...

Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

This year, the EHA Congress provided us with long-term follow-up of some very interesting study, including the GAIA/CLL13 ...

We appreciate the opportunity to address the comments by Yangfan Cheng and colleagues, and Sebastian Walsh and colleagues regarding our Article on long-term gantenerumab treatment in dominantly ...

Introduction Tocilizumab improves outcomes in critically ill patients with COVID-19. Whether other immune-modulator strategies are equally effective or better is unknown. Methods We investigated ...

Fund announced today a total investment of approximately JPY 1 billion (USD 7.3 million1) in four R&D projects for the development of vaccine, drug, and diagnostics for malaria and tuberculosis (TB).2 ...